Loading stock data…
Immunocore Holdings plc (IMCR)
$30.42-0.46 (-1.49%)
Market ClosedLast close Jun 29
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immunocore Holdings plc in the Healthcare sector is trading at $30.42 with a market capitalization of $1.4B. Wall Street consensus targets $63.49 (13 analysts), implying a +108.7% move over the next 12 months. The stock is currently 25% below its 52-week high of $40.72, remaining 6.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +108.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $106.68M↑ | $104.48M↑ | $103.69M↑ | $97.96M↑ | $93.88M |
| Gross Profit | $106.24M↑ | $101.78M↓ | $103.18M↑ | $96.92M↑ | $93.05M |
| Operating Income | $7.28M↑ | -$19.69M↓ | -$7.17M↑ | -$14.88M↓ | -$3.62M |
| Net Income | $12.97M↑ | -$30.06M↓ | -$177,000↑ | -$10.30M↓ | $5.02M |
Peer Comparison
JNJUNHPFE
Fundamentals
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internatio...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.44B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-7.00%
Volume
Today's trading volume
499,147
Recent News
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?
Krystal Biotech (KRYS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization and securing upfront and royalty payments.
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipeline reinforce Kiniksa's growth strategy.
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
KYMR stock soars 17% as investor optimism was lifted following early enrollment completion in mid-stage AD study, moving KT-621 top-line data to year-end 2026.